 Prostatic Neoplasms, Castration-Resistant
"Prostatic Neoplasms, Castration-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PROSTATE which can grow in the presence of low or residual amount of androgen hormones such as TESTOSTERONE.
| Descriptor ID |
D064129
|
| MeSH Number(s) |
C04.588.945.440.770.500 C12.294.260.750.500 C12.294.565.625.500 C12.758.409.750.500
|
| Concept/Terms |
Prostatic Neoplasms, Castration-Resistant- Prostatic Neoplasms, Castration-Resistant
- Castration-Resistant Prostatic Neoplasm
- Neoplasm, Castration-Resistant Prostatic
- Neoplasms, Castration-Resistant Prostatic
- Prostatic Neoplasm, Castration-Resistant
- Prostatic Neoplasms, Castration Resistant
- Androgen-Insensitive Prostatic Neoplasms
- Androgen Insensitive Prostatic Neoplasms
- Androgen-Resistant Prostatic Neoplasms
- Androgen Resistant Prostatic Neoplasms
- Prostatic Neoplasms, Hormone Refractory
- Hormone Refractory Prostatic Neoplasms
- Prostatic Neoplasms, Androgen-Independent
- Androgen-Independent Prostatic Neoplasm
- Neoplasm, Androgen-Independent Prostatic
- Neoplasms, Androgen-Independent Prostatic
- Prostatic Neoplasm, Androgen-Independent
- Prostatic Neoplasms, Androgen Independent
- Prostatic Neoplasms, Androgen-Insensitive
- Androgen-Insensitive Prostatic Neoplasm
- Neoplasm, Androgen-Insensitive Prostatic
- Neoplasms, Androgen-Insensitive Prostatic
- Prostatic Neoplasm, Androgen-Insensitive
- Prostatic Neoplasms, Androgen Insensitive
- Prostatic Neoplasms, Androgen-Resistant
- Androgen-Resistant Prostatic Neoplasm
- Neoplasm, Androgen-Resistant Prostatic
- Neoplasms, Androgen-Resistant Prostatic
- Prostatic Neoplasm, Androgen-Resistant
- Prostatic Neoplasms, Androgen Resistant
- Androgen-Independent Prostatic Neoplasms
- Androgen Independent Prostatic Neoplasms
- Castration-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
Prostatic Cancer, Castration-Resistant- Prostatic Cancer, Castration-Resistant
- Cancer, Castration-Resistant Prostatic
- Cancers, Castration-Resistant Prostatic
- Castration-Resistant Prostatic Cancers
- Prostatic Cancer, Castration Resistant
- Prostatic Cancers, Castration-Resistant
- Androgen-Insensitive Prostatic Cancer
- Androgen Insensitive Prostatic Cancer
- Androgen-Resistant Prostatic Cancer
- Androgen Resistant Prostatic Cancer
- Prostatic Cancer, Hormone Refractory
- Hormone Refractory Prostatic Cancer
- Prostatic Cancer, Androgen-Independent
- Androgen-Independent Prostatic Cancers
- Cancer, Androgen-Independent Prostatic
- Cancers, Androgen-Independent Prostatic
- Prostatic Cancer, Androgen Independent
- Prostatic Cancers, Androgen-Independent
- Prostatic Cancer, Androgen-Insensitive
- Androgen-Insensitive Prostatic Cancers
- Cancer, Androgen-Insensitive Prostatic
- Cancers, Androgen-Insensitive Prostatic
- Prostatic Cancer, Androgen Insensitive
- Prostatic Cancers, Androgen-Insensitive
- Prostatic Cancer, Androgen-Resistant
- Androgen-Resistant Prostatic Cancers
- Cancer, Androgen-Resistant Prostatic
- Cancers, Androgen-Resistant Prostatic
- Prostatic Cancer, Androgen Resistant
- Prostatic Cancers, Androgen-Resistant
- Androgen-Independent Prostatic Cancer
- Androgen Independent Prostatic Cancer
- Castration-Resistant Prostatic Cancer
- Castration Resistant Prostatic Cancer
|
Below are MeSH descriptors whose meaning is more general than "Prostatic Neoplasms, Castration-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Prostatic Neoplasms, Castration-Resistant".
This graph shows the total number of publications written about "Prostatic Neoplasms, Castration-Resistant" by people in this website by year, and whether "Prostatic Neoplasms, Castration-Resistant" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 2 | 0 | 2 | | 2014 | 2 | 1 | 3 | | 2015 | 4 | 0 | 4 | | 2016 | 3 | 0 | 3 | | 2017 | 1 | 1 | 2 | | 2019 | 5 | 0 | 5 | | 2020 | 1 | 0 | 1 | | 2021 | 2 | 0 | 2 | | 2022 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Prostatic Neoplasms, Castration-Resistant" by people in Profiles.
-
Dutta S, Polavaram NS, Islam R, Bhattacharya S, Bodas S, Mayr T, Roy S, Albala SAY, Toma MI, Darehshouri A, Borkowetz A, Conrad S, Fuessel S, Wirth M, Baretton GB, Hofbauer LC, Ghosh P, Pienta KJ, Klinkebiel DL, Batra SK, Muders MH, Datta K. Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene. 2022 Jul; 41(30):3747-3760.
-
Stein MN, Fong L, Tutrone R, Mega A, Lam ET, Parsi M, Vangala S, Gutierrez AA, Haas NB. ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. Oncologist. 2022 Jun 08; 27(6):453-461.
-
Liu AJ, Kosiorek HE, Ueberroth BE, Jaeger E, Ledet E, Kendi AT, Tzou K, Quevedo F, Choo R, Moore CN, Ho TH, Singh P, Keole SR, Wong WW, Sartor O, Bryce AH. The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases. Prostate. 2022 Sep; 82(12):1202-1209.
-
Graham LS, Schweizer MT. Mismatch repair deficiency and clinical implications in prostate cancer. Prostate. 2022 08; 82 Suppl 1:S37-S44.
-
Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, Thomas S, Bevans KB, Mundle SD, McCarthy SA, Rathkopf DE. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559.
-
Petrylak DP, Ratta R, Gafanov R, Facchini G, Piulats JM, Kramer G, Flaig TW, Chandana SR, Li B, Burgents J, Fizazi K. KEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer. Future Oncol. 2021 Sep; 17(25):3291-3299.
-
Chen Y, Li X, Mamouni K, Yang Y, Danaher A, White J, Liu H, Kucuk O, Gera L, Wu D. Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer. Prostate. 2020 09; 80(12):993-1005.
-
Yu EY, Hancock ML, Aronson W, Flaig T, Belkoff L, Tutrone R, Taylor R, Hardigan PC, Getzenberg RH. Phase 2 Trial of GTx-758, an Estrogen Receptor Alpha Agonist, in Men With Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2020 12; 18(6):436-443.
-
Lee YG, Nam Y, Shin KJ, Yoon S, Park WS, Joung JY, Seo JK, Jang J, Lee S, Nam D, Caino MC, Suh PG, Chan Chae Y. Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. Cancer Lett. 2020 02 28; 471:72-87.
-
Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer BC. Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urol Oncol. 2020 01; 38(1):1.e1-1.e10.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|